Akash Tewari
Stock Analyst at Jefferies
(2.33)
# 2,662
Out of 5,090 analysts
61
Total ratings
39.13%
Success rate
2.4%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $29.36 | +19.21% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $81.68 | +17.53% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $718.36 | +15.68% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $13.07 | +98.93% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $12.79 | -21.81% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $52.15 | +30.39% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $53.40 | +77.90% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $96.25 | +55.84% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $7.68 | +108.33% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $155.51 | +21.54% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $23.63 | +238.55% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $1,010.31 | +0.46% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $29.52 | +69.38% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $76.75 | -2.28% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $33.45 | -7.32% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $26.03 | +49.83% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $14.60 | +23.29% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $901.17 | -43.07% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $99.72 | +25.35% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $26.69 | -58.79% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $2.37 | +617.30% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $65.67 | +14.21% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $577.30 | -73.84% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $44.36 | -36.88% | 3 | Oct 7, 2021 |
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $29.36
Upside: +19.21%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $81.68
Upside: +17.53%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $718.36
Upside: +15.68%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $13.07
Upside: +98.93%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $12.79
Upside: -21.81%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $52.15
Upside: +30.39%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $53.40
Upside: +77.90%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $96.25
Upside: +55.84%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $7.68
Upside: +108.33%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $155.51
Upside: +21.54%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $23.63
Upside: +238.55%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $1,010.31
Upside: +0.46%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $29.52
Upside: +69.38%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $76.75
Upside: -2.28%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $33.45
Upside: -7.32%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $26.03
Upside: +49.83%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $14.60
Upside: +23.29%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $901.17
Upside: -43.07%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $99.72
Upside: +25.35%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $26.69
Upside: -58.79%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $2.37
Upside: +617.30%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $65.67
Upside: +14.21%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $577.30
Upside: -73.84%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $44.36
Upside: -36.88%